Robert E. Hoffman - 15 Feb 2022 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)

Role: President and CEO, Director
Signature: /s/ Anthony Scott Praill, attorney-in-fact for Robert E. Hoffman
Issuer symbol: HURA
Transactions as of: 15 Feb 2022
Net transactions value: +$25,795
Form type: 4
Filing time: 17 Feb 2022, 15:00:46 UTC
Previous filing: 10 Nov 2021
Next filing: 03 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KTRA	Common Stock	Purchase	$25,795	+55,000		$0.4690^*	55,000	15 Feb 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.